---
title: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease
euct_id: 2023-504412-14-00
eudra_ct_number: 2021-002345-15
phase: Phase 3
status: Completed
sponsor: F. Hoffmann-La Roche AG
canonical_url: "https://parkinsonspathways.com/trials/eu/2023-504412-14-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2023-504412-14-00"
ctis_last_updated: "2025-10-22T03:40:32.354528614"
source: EU Clinical Trials Information System (CTIS)
---
# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease

**EU CT Number:** [2023-504412-14-00](https://euclinicaltrials.eu/ctis-public/view/2023-504412-14-00)

## Key Facts

- **Phase:** Phase 3
- **Status:** Completed
- **Sponsor:** F. Hoffmann-La Roche AG
- **Start Date:** 2022-11-14
- **Completion Date:** 2023-11-14
- **Conditions:** Early Idiopathic Parkinson’s Disease (PD), Parkinson's disease

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (3)

- Brain Research Center Amsterdam B.V., Amsterdam, Netherlands
- Stichting Radboud University Medical Center, Nijmegen, Netherlands
- Brain Research Center Zwolle B.V., Zwolle, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Early Idiopathic Parkinson’s Disease (PD); Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2023-504412-14-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2023-504412-14-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2023-504412-14-00*